{"id":1252,"date":"2026-08-05T23:44:23","date_gmt":"2026-08-05T23:44:23","guid":{"rendered":"https:\/\/myhealtho.com\/news\/half-of-vaccines-are-binned-fridge-free-versions-could-change-that\/"},"modified":"2026-08-05T23:44:23","modified_gmt":"2026-08-05T23:44:23","slug":"half-of-vaccines-are-binned-fridge-free-versions-could-change-that","status":"publish","type":"post","link":"https:\/\/myhealtho.com\/news\/half-of-vaccines-are-binned-fridge-free-versions-could-change-that\/","title":{"rendered":"Half of vaccines are binned – ‘fridge-free’ versions could change that"},"content":{"rendered":"
\"Half<\/figure>\n
\"Half<\/figure>\n
\"Half<\/figure>\n
\"Half<\/figure>\n
\"Half<\/figure>\n

Scientists in the UK have achieved a significant milestone in vaccine technology: for the first time, a vaccine that doesn’t require refrigeration has been successfully tested in human volunteers. This breakthrough could dramatically reduce the staggering amount of vaccines discarded each year and make immunization more accessible worldwide.<\/p>\n

The Problem: A Global Cold Chain Crisis<\/h2>\n

Most vaccines currently on the market are delicate biological products that must be kept within a strict temperature range\u2014typically between 2\u00b0C and 8\u00b0C\u2014from the moment they are manufactured until the moment they are injected. This unbroken chain of refrigeration, known as the “cold chain,” is one of the biggest logistical hurdles in global health.<\/p>\n

According to the World Health Organization (WHO), approximately half of all vaccines produced globally are wasted every year. The reasons are varied: some are damaged during transport, some expire before use, and some are discarded when multi-dose vials are opened but not fully used. However, a major contributor is the failure of the cold chain itself. When vaccines are exposed to temperatures that are too high or too low, their active components can degrade, rendering them ineffective. In many parts of the world\u2014especially in remote, low-income regions or conflict zones\u2014maintaining a consistent cold chain is nearly impossible due to unreliable electricity, lack of refrigeration equipment, and poor road infrastructure.<\/p>\n

The Human Cost of Vaccine Waste<\/h3>\n

This waste has real consequences. Children in the most vulnerable communities often miss out on life-saving immunizations simply because vaccines cannot reach them in a usable state. Health workers in remote clinics face the constant anxiety of transporting vaccines in cool boxes over rough terrain, hoping that the cold chain holds long enough to get the shots into the arms of waiting children.<\/p>\n

Professor Sir Jonathan Van-Tam, former deputy chief medical officer for England and now an advisor to the biotech company behind this new technology, knows this challenge firsthand. He recalls his time working in remote field clinics: “I can remember taking out vaccines in cool boxes\u2026 doing that on really inhospitable roads where one couldn’t predict getting from A to B in a short period of time and there was always this nervousness about maintaining the cold chain in time to get the vaccines into arms of waiting children.”<\/p>\n

The Breakthrough: Nature-Inspired Vaccine Stabilization<\/h2>\n

The new approach, developed by the UK company Stablepharma, takes inspiration from an unlikely source: the resurrection plant. These remarkable plants can survive extreme drought, drying out completely and appearing dead, only to spring back to life when rain returns. The secret lies in a natural sugar called trehalose, which the plant produces in large quantities during dry periods. This sugar stabilizes the plant’s cells, protecting them from damage caused by dehydration.<\/p>\n

Stablepharma has applied this same principle to vaccines. In their process, a liquid vaccine is mixed with trehalose and then dried into a powder. The sugar forms a protective matrix around the vaccine’s active ingredients, keeping them stable even at room temperature. When it’s time to administer the vaccine, the powder is simply mixed with water and injected.<\/p>\n

Successful First Human Trial<\/h3>\n

The company tested this technology with a combined tetanus-diphtheria vaccine. In a clinical trial involving 60 volunteers, the fridge-free version was stored as a dry powder at room temperature for a full year before being reconstituted and administered. The results, published in the Lancet journal eClinicalMedicine<\/em>, were encouraging: the fridge-free vaccine produced immune responses equivalent to those of the conventional vaccine, and it was found to be safe and well tolerated.<\/p>\n

Professor Saul Faust, director of the NIHR Clinical Research Facility in Southampton, which conducted the trial, said the vaccine gave “equivalent” immune responses and was “safe and well tolerated.” He added: “This obviously has potential to remove cold chain dependence, reduce wastage and improve access.”<\/p>\n

What This Means for Global Health<\/h2>\n

The implications of this breakthrough are profound. If vaccines can be stored and transported without refrigeration, they become far easier to distribute in low-resource settings. No longer would health workers need to worry about keeping vaccines cold during long journeys over rough roads or in hot climates. They could simply carry the dry powder vials in their bags, mix them with water on-site, and administer them.<\/p>\n

This could also reduce costs. The cold chain requires significant investment in refrigerated vehicles, cold storage facilities, and monitoring equipment. Removing this requirement would make immunization programs more affordable and sustainable, particularly in developing countries.<\/p>\n

Ephrem Tekle Lemango, associate director of immunization at UNICEF, welcomed the development: “Immunisation is a life-saving service that depends on refrigeration. This innovation could help us vaccinate more children and pave the way for a future of fridge-free vaccines.”<\/p>\n

Beyond Vaccines: Potential for Other Medicines<\/h3>\n

The technology isn’t limited to vaccines. Many other medical products, such as monoclonal antibodies and certain biologics, also require strict temperature control. If these could be stabilized using the same trehalose-based approach, it could revolutionize the storage and distribution of a wide range of life-saving medicines.<\/p>\n

However, not all vaccines can be adapted this way. The new mRNA vaccines, like those used for COVID-19, are particularly fragile and may not be compatible with this drying technique. But many traditional vaccines\u2014including those for tetanus, diphtheria, and potentially others\u2014could benefit.<\/p>\n

What’s Next: Larger Trials and Regulatory Approval<\/h2>\n

The early success has paved the way for a larger trial involving 160 participants, which is expected to begin in the coming months. This will be the final stage of research, as the original tetanus-diphtheria vaccine is already approved and licensed. There is no need for the massive Phase III trials typically required for novel vaccines; instead, the focus is on demonstrating that the fridge-free version is as effective and safe as the original.<\/p>\n

The trials are designed to meet the World Health Organization’s goal of a vaccine that can survive at 30\u00b0C and 75% relative humidity. But the research team has even more ambitious data: their vaccine components have also been shown to survive cycling between -20\u00b0C and +40\u00b0C. This means the vaccine could potentially be transported in the cold hold of an aircraft and then in the back of a truck in sweltering heat without losing potency.<\/p>\n

Expert Perspectives and Cautions<\/h3>\n

Professor Tuck Seng Wong, director of the UK-Southeast Asia Vaccine Manufacturing Research Hub, was not involved in the study but described it as “very exciting” and a “significant breakthrough in UK science.” However, he also noted that there are still “several areas” requiring further investigation. These include how well the vaccines hold up when temperatures fluctuate regularly (as opposed to steady storage) and how the vaccine performs in larger and more ethnically diverse populations.<\/p>\n

Dr. Bruce Roser, founder of Stablepharma, is optimistic about the future: “Reliable and safe fridge-free vaccines could be a game-changer for global health\u2014helping life-saving vaccines reach millions more people, wherever they live, and making immunisation programmes more sustainable, reliable and equitable for future generations.”<\/p>\n

A Future Without the Cold Chain<\/h2>\n

This breakthrough brings us closer to a world where the cold chain is no longer a barrier to immunization. For decades, the need for constant refrigeration has been one of the greatest obstacles to global vaccine coverage. It has meant that vaccines often cannot reach the people who need them most\u2014those in remote villages, refugee camps, and conflict zones.<\/p>\n

By harnessing the power of a humble sugar found in desert plants, scientists have found a way to make vaccines as hardy as the plants that inspired them. The potential impact is enormous: fewer vaccines wasted, more children protected, and a more equitable distribution of life-saving immunizations across the globe.<\/p>\n

While there is still work to be done\u2014larger trials, regulatory approvals, and scaling up production\u2014the promise is clear. The era of fridge-free vaccines may be just around the corner, and it could change the face of global health forever.<\/p>\n","protected":false},"excerpt":{"rendered":"

Scientists in the UK have achieved a significant milestone in vaccine technology: for the first time, a vaccine that doesn’t require refrigeration has been successfully tested in human volunteers. This breakthrough could dramatically reduce the staggering amount of vaccines discarded each year and make immunization more accessible worldwide. The Problem: A Global Cold Chain Crisis…<\/p>\n","protected":false},"author":1,"featured_media":1247,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/posts\/1252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/comments?post=1252"}],"version-history":[{"count":0,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/posts\/1252\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/media?parent=1252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/categories?post=1252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myhealtho.com\/news\/wp-json\/wp\/v2\/tags?post=1252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}